TransMedics (TMDX) Current Deferred Revenue (2018 - 2026)

TransMedics has reported Current Deferred Revenue for 9 years, with the latest figure at $3.1 million in Q2 2026.

• On a quarterly basis, Current Deferred Revenue rose 99.36% year-over-year to $3.1 million in Q2 2026; TTM through Jun 2026 was $3.1 million, a 99.36% increase from a year earlier, with the FY2025 full-year figure at $2.9 million, up 66.76% from the prior year.
• Current Deferred Revenue was $3.1 million for Q2 2026 at TransMedics, up from $2.9 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $3.3 million in Q3 2025, with the low at $226000.0 in Q3 2022.
• Average Current Deferred Revenue over 5 years is $1.6 million, with a median of $1.9 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue slumped 49.68% in 2022, then jumped 1063.27% in 2023.
• Over 5 years, Current Deferred Revenue stood at $241000.0 in 2022, then jumped by 713.69% to $2.0 million in 2023, then retreated by 11.17% to $1.7 million in 2024, then jumped by 66.76% to $2.9 million in 2025, then rose by 7.75% to $3.1 million in 2026.
• The last three Current Deferred Revenue figures came in at $3.1 million (Q2 2026), $2.9 million (Q1 2026), and $2.9 million (Q4 2025), per Business Quant data.